RELMADA THERAPEUTICS Executives Make Significant Stock Purchases in May 2025
| Reporter Name | Relationship | Type | Amount | SEC Filing |
|---|---|---|---|---|
| Traversa Sergio | Chief Executive Officer | Purchase | $174,712 | Form 4 |
| Ence Chuck | CA and CO | Purchase | $103,330 | Form 4 |
| Shenouda Maged | Chief Financial Officer | Purchase | $97,208 | Form 4 |
| Kelly Paul Edward | Chief Operating Officer | Purchase | $86,060 | Form 4 |
Sergio Traversa, the CEO of RELMADA THERAPEUTICS, has significantly increased his stake in the company by purchasing 350,000 shares across three transactions on May 16, May 19, and May 20, 2025, for a total of $174,712. The weighted average prices for these shares were $0.4496, $0.4998, and $0.5569, respectively, bringing his direct ownership to 734,024 shares.
Chuck Ence, titled CA and CO, acquired 228,961 shares on May 16, 2025, at a weighted average price of $0.4513 per share, amounting to $103,330. This purchase increased his direct ownership to 267,931 shares.
Maged Shenouda, the CFO, also participated in the buying, securing 200,000 shares through transactions on May 16, May 19, and May 20, 2025, for a total of $97,208. The weighted average prices per share were $0.442, $0.4854, and $0.5237, respectively, raising his direct ownership to 288,335 shares.
Paul Edward Kelly, the COO, purchased 200,000 shares on May 16, 2025, at a weighted average price of $0.4303 per share, totaling $86,060. This transaction increased his direct ownership to 412,295 shares.